Streamlining the screening cascade for active Hepatitis C in Russia: A cost-effectiveness analysis
Rattachement africain : de, ru. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
OBJECTIVE: Screening for hepatitis C in Russia is a complex process that involves several visits and stepwise testing, limiting adherence and substantially reducing the yield in the identification of active infections. We aimed to evaluate the cost-effectiveness of different screening algorithms from a health system perspective. METHODS: A decision analytic model was applied to a hypothetical adult population eligible to participate in a general screening program for hepatitis C in Russia. The standard pathway (I: Screen for anti-HCV antibodies followed by a nucleic acid test for HCV RNA on antibody positives) was compared to three alternatives (II: Screen for antibodies, a reflexed test for HCV antigen on antibody positives, and RNA on antigen negatives; III: Screen for antibodies, a reflexed test for HCV antigen on antibody positives; IV: Screen for antigen). Each strategy considered a cascade of events (referral, adherence, testing, diagnosis) that must occur for screening to be effective. The primary measure of effectiveness was the number of diagnosed active infections. Calculations followed a health system perspective with costs derived from 2017 reimbursement rates and a willingness-to-pay of 2,000RUB ($82) per diagnosed active infection. Model was tested with deterministic and probabilistic sensitivity analyses. RESULTS: Non-adherence to screening stages reduced the capture rate of active infections in Strategy I from 79.0% to 40.6%. Strategies II, III, and IV were less affected and identified 69%, 67%, and 104% more infections. Average costs per diagnosed infection were decreased by 41% from 89,599RUB ($3,681) for I to 53,072RUB ($2,180), 53,004RUB ($2,177), and 59,633RUB ($2,450) for II, III, and IV, respectively. With a probability of 97%, Strategy III was most cost-effective with an incremental cost-effectiveness ratio vs. I of -1,373RUB (CI: -5,011RUB to -2,033RUB; $-56; CI: -$206 to -$84). Below a willingness-to-pay of 91,000RUB ($3,738), Strategy IV was not cost-effective. Sensitivity analyses confirmed the robustness of results. CONCLUSIONS: Testing strategies for hepatitis C with HCV antigen on HCV antibody positive cases offer a streamlining opportunity for population screening programs. Those shall increase the chances for detecting active infections and are cost-effective over current practice in Russia.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Streamlining the screening cascade for active Hepatitis C in Russia: A cost-effectiveness analysis
- Date Crossref
- 16/07/2019
- Éditeur
- Public Library of Science (PLoS)
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Abbott (Germany) pays non établi dans la noticeEntreprise
-
Sechenov University pays non établi dans la noticeUniversité ou école supérieure
-
Central Research Institute of Epidemiology Reference Center for Viral Hepatitis pays non établi dans la noticeStructure de recherche
-
Centre for Independent Social Research pays non établi dans la noticeOrganisme public
-
Health Economics and Outcomes Research pays non établi dans la noticeInstitution
-
I.M. Sechenov First Moscow State Medical University pays non établi dans la noticeUniversité ou école supérieure
-
CIS pays non établi dans la noticeInstitution
-
Medical Communication pays non établi dans la noticeInstitution
-
Global Medical & Scientific Affairs pays non établi dans la noticeInstitution
Abbott (Germany), Sechenov University et Reference Center for Viral Hepatitis — Central Research Institute of Epidemiology, avec 6 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.